VERAXA Biotech Advances Dual-Targeting Cancer Pipeline

VERAXA Biotech (NASDAQ: VRXA) is making significant strides in the fight against cancer with its innovative approach to antibody-based therapies. The company's proprietary BiTAC platform employs a dual-targeting, 'AND-gated' architecture designed to activate therapeutic effects preferentially at tumor sites, thereby reducing off-target toxicity. This precision is central to VERAXA's mission to change how antibody-based therapies recognize and attack cancer cells. The company is developing bispecific antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other engineered antibody formats, with a focus on enhancing efficacy and safety.

The latest pipeline advancement sees VXA-222, a bispecific ADC, moving beyond the initial discovery phase after completing the antibody-discovery step with OmniAb. VERAXA is now engineering the final therapeutic candidate using the binders generated through this collaboration. Additionally, the lead BiTAC-TCE has advanced toward IND/CTA-enabling activities, following cell-line development and regulatory feedback from Germany's Paul-Ehrlich-Institute. The company also boasts a robust intellectual property portfolio, with more than 50 granted patents across 26 patent families in 14 countries. For more details, read the full press release.

VERAXA's progress is a testament to its strategic collaborations and scientific expertise. As the company continues to advance its pipeline, it is positioning itself as a key player in the oncology space, with the potential to offer more precise and effective cancer treatments. Investors and industry watchers can stay updated on VRXA's developments through the company's newsroom at https://nnw.fm/VRXA.